Curanex Pharmaceuticals Inc. has added cancer cachexia to its drug‑development pipeline, expanding its focus beyond its current inflammatory and metabolic indications. The company highlighted the global market for cancer cachexia, estimating a 2024 size of approximately $2.54 billion and a projected $3.90 billion by 2033, underscoring a sizable unmet need.
Curanex’s lead program, Phyto‑N, remains in preclinical development for ulcerative colitis. The company has completed a GMP‑compliant pilot‑scale batch of Phyto‑N, which will support GLP toxicology and pharmacokinetic studies ahead of a planned IND submission for ulcerative colitis in the fourth quarter of 2026.
Cancer cachexia affects up to 80 % of patients with advanced cancer, and market research shows divergent estimates. Grand View Research cites a 2024 market of $2.54 billion, while other reports project $3.3 billion or $2.2 billion for the same year, with 2033 projections ranging from $3.0 billion to $5.1 billion. DelveInsight estimates a 7‑market segment value of $475 million in 2024, growing to $1.038 billion by 2034.
CEO Jun Liu said, "Cancer cachexia remains one of the largest unmet needs in supportive oncology, with serious consequences for patients and very limited treatment options. We believe this area represents a meaningful opportunity for focused drug development and an important step in the evolution of Curanex into a broader therapeutics development company."
As a development‑stage, pre‑revenue company, the announcement does not generate immediate financial impact but signals a strategic pivot toward a high‑potential therapeutic area. The addition of cancer cachexia broadens Curanex’s pipeline and positions the company to pursue a market that currently lacks approved therapies, potentially setting the stage for future clinical development and partnership opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.